Cancer researchers embrace AI to accelerate development of precision medicine

Biomedical researchers are embracing artificial intelligence to accelerate the implementation of cancer treatments that target patients’ specific genomic profiles, a type of precision medicine that in some cases is more effective than traditional chemotherapy and has fewer side effects.

The potential for this new era of cancer treatment stems from advances in genome sequencing technology that enables researchers to more efficiently discover the specific genomic mutations that drive cancer, and an explosion of research on the development of new drugs that target those mutations.

To harness this potential, researchers at The Jackson Laboratory, an independent, nonprofit biomedical research institution also known as JAX and headquartered in Bar Harbor, Maine, developed a tool to help the global medical and scientific communities stay on top of the continuously growing volume of data generated by advances in genomic research.